Braftovi (encorafenib) — Medica
Non-Small Cell Lung Cancer
Initial criteria
- age ≥ 18 years
- patient has recurrent, advanced, or metastatic disease
- patient has BRAF V600E mutation-positive disease
- the medication will be taken in combination with Mektovi (binimetinib)
Approval duration
1 year